| Presentation preference | Poster presentation |
| Title | Inflammatory IOL opacification |
| Purpose | To report 5 cases of inflammatory early postoperative IOL opacification in a series of 897 consecutive phaco surgeries |
| Methods | Single center, consecutive, case series. Internal and external audit of the procedures |
| Results | All 897 cases were operated on using the same viscoelastic, IOL model and intraocular solution. IOL opacification occurred to 4 different surgeons in Sep 2018, Dec 2018, Mar 2019, May 2019 and Jul 2019, after uneventful surgery and were identified at the scheduled visit between 1 and 2 months after surgery. Patients presented with a thin fibrinous membrane on the anterior surface of the IOL and mild flare. They were treated with topical steroids (5 cases), Nd-YAG laser anterior to the IOL surface (3 cases), transTenon triamcinolone (1 case) and anterior chamber rinse (1 case) that was negative for bacterial or fungal culture. Final corrected visual acuity was between 4/8 and 4/5. None of the patients experienced recurrences or similar events during fellow eye surgery.
None of the patients had history of systemic or ocular inflammatory conditions or previous intraocular procedures. In 3 patients It was associated with pseudoexfoliation and in 2 cases with atrophic AMD.
A thorough audit of the surgical and sterilization procedures and adjuvant materials used during the surgeries was performed by two teams (internal and external) and no causes were found that might be related to the occurrence of these inflammatory events.
No similar cases have been identified since, even though the same procedures have been maintained |
| Conclusion | We report 5 cases of early postoperative inflammation with IOL opacification successfully treated by topical steroids combined with other minor procedures. The cause of IOL opacification has remained unknown. |
| Conflict of interest | No |
Authors 1
| Last name | MONTERO-MORENO |
| Initials of first name(s) | J |
| Department | Ophthalmology. Rio Hortega Hospital |
| City | Valladolid |
| Country | Spain |
Authors 2
| Last name | Diez-Montero |
| Initials of first name(s) | C |
| Department | Ophthalmology. Rio Hortega Hospital |
| City | Valladolid |
| Country | Spain |
Authors 3
| Last name | Sanchis-Merino |
| Initials of first name(s) | ME |
| Department | Allergy and Clinical Immunology. Rio Hortega Hospital |
| City | Valladolid |
| Country | Spain |
Authors 4
| Last name | Gonzalez-Uruena |
| Initials of first name(s) | C |
| Department | Ophthalmology Clinical Trials Unit. Rio Hortega Hospital |
| City | Valladolid |
| Country | Spain |
Authors 5
| Last name | Hernandez-Fernandez |
| Initials of first name(s) | R |
| Department | Ophthalmology Clinical Trials Unit. Rio Hortega Hospital |
| City | Valladolid |
| Country | Spain |
Authors 6
| Last name | Cañibano-Perez |
| Initials of first name(s) | E |
| Department | Ophthalmology Clinical Trials Unit. Rio Hortega Hospital |
| City | Valladolid |
| Country | Spain |
